Clinical Trial Update: Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravitreal hI-con1 for choroidal neovascularization due to age-related macular degeneration has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• hI-con1

Snippet

Sponsor: Iconic Therapeutics, Inc. | Conditions: Choroidal Neovascularization, Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2020-09-24